{"id":"W4387810248","doi":"10.1016/j.annonc.2023.09.2753","title":"1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; AstraZeneca España; Genentech; UroGen Pharma; Advanced Accelerator Applications; Sanofi Genzyme; Pfizer; Incyte; Ipsen; BeiGene; Constellation Pharmaceuticals; Clovis Oncology; Sanofi; Exelixis; Boston Scientific Corporation; Les Laboratories Pierre Fabre; Teva Pharmaceutical Industries; AstraZeneca; Invitae; Daiichi Sankyo Europe; Gilead Sciences; Amgen","keywords":"Medicine; Abiraterone; Prostate cancer; Oncology; Placebo; Internal medicine; Olaparib; BRCA mutation; Cancer; Urology; Gynecology; Ovarian cancer; Androgen receptor; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005811135,0.0006263792,0.001233646,0.0002147575,0.0001757414,0.0009028823,0.0004249107,0.0005598817,0.008039304],"category_scores_gemma":[0.001072701,0.0002256139,0.001194009,0.0002911734,0.000356173,0.0005278174,0.0002990422,0.001746575,0.0008038136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004916782,"about_ca_system_score_gemma":0.0007457561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006003933,"about_ca_topic_score_gemma":0.001435457,"domain_scores_codex":[0.9997588,0.0001197011,0.00001580438,0.00003566674,0.00001721552,0.00005283704],"domain_scores_gemma":[0.9996401,0.0001267504,0.00006101621,0.00002107214,0.00001471272,0.000136343],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9184785,0.001363838,0.001889388,0.0006655295,0.001175613,0.00008453354,0.00004107023,0.0009160081,0.003568298,0.000463326,0.00288117,0.06847265],"study_design_scores_gemma":[0.8093994,0.1506558,0.02092137,0.0002862308,0.003038129,0.0003365743,0.0001409148,0.002230177,0.002327114,0.002529382,0.008076104,0.00005883369],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776508,0.009066346,0.0003680103,0.001778845,0.0005768059,0.0003957771,0.002135812,0.0001480312,0.007879564],"genre_scores_gemma":[0.9932759,0.00199466,0.0003100674,0.0008027197,0.0002572786,0.0002200041,0.001112227,0.00001461478,0.002012542],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008039304,"threshold_uncertainty_score":0.02689415,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08187992572353721,"score_gpt":0.3951942629746705,"score_spread":0.3133143372511333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}